Financial Highlights
Revenue reached RMB1,729.4 million
Gross profit amounted to RMB655.6 million
Gross profit margin recorded 37.9%, a YOY increase of 3.3 pp
Net profit recorded RMB269.3 million, a YOY increase 21.3%
Adjusted non-IFRS net profit recorded RMB335.3 million, a YOY increase of nearly 6.6%
SHANGHAI, March 30, 2026 /PRNewswire/ — On March 30, 2026, Viva Biotech Holdings (“Viva Biotech”, “the Group” or “the Company”, stock code: 1873.HK) announced that for the Group’s revenue amounted to RMB1,729.4 million during the Reporting Period, with gross profit of RMB655.6 million. The Group’s gross profit margin was 37.9%, representing an increase of 3.3 percentage points compared with the same period last year, mainly attributable to the optimization and adjustment of Langhua Pharmaceutical’s business mix, improved operational efficiency of the CRO business. Throughout 2025, the Group’s net profit was RMB269.3 million, representing a year-on-year increase of 21.3% compared with RMB220.0 million in the same period last year. Adjusted non-IFRS net profit increased from RMB314.6 million in the same period last year to RMB335.3 million, representing a year-on-year increase of approximately 6.6%, which was mainly due to the revenue growth of the CRO business, improved profitability arising from the optimization of Langhua Pharmaceutical’s business mix, as well as investment income from the successful exit from incubation portfolio companies.
CRO Business Sustained Recovery in …